News | April 22, 2023
CCI approves Berhyanda's acquisition of Suven Pharma
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Subscribe To Our Newsletter & Stay Updated
